Matt Gline

Synopsis: Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – nimble, entrepreneurial biotech and healthcare technology companies. Matt discusses his transition from CFO to CEO at Roivant and how he prepared to step into the CEO role for the first time. He talks about Roivant’s model and how it’s different from other biotech companies, and how the current market conditions inform how Roivant operates across its portfolio. He also discusses some of the inefficiencies across biotech and where he sees room for improvement, how telemedicine emerged as a silver lining from the pandemic, and his thoughts on the current labor market. Biography: Matthew Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Matt Gline, CEO of Roivant Sciences, shares insights from his journey in biotech leadership. He discusses the transformative $7B deal with Roche, emphasizing disciplined execution and their decentralized 'Vant' model that allows multiple CEOs to thrive. Gline reveals the importance of tailored clinical trial designs, particularly in challenging conditions like dermatomyositis. He reflects on cultivating a creative team and adapting to the evolving biotech financing landscape. Authenticity and lessons learned from both successes and failures play a key role in his leadership philosophy.

Matt Gline, CEO of Roivant, joins hosts to discuss recent Phase 1 data from Immunovant, biotech sentiment, M&A, state of the XBI, BridgeBio PIPE funding, Alfasigma acquires Intercept Pharmaceuticals, setbacks for two CD47s, Apellis Favus short report, and drug pricing negotiations.